EmailStory Stocks®
Archive
Last Update: 08-Dec-11 11:16 ET
Affymax Up 38% On Positive Drug News Out After The Close Yesterday
Late yesterday, Affymax (AFFY $8.06 +2.20) reported FDA Advisory Committee voted in favor of Benefit/Risk Profile for Peginesatide for treatment of anemia in chronic kidney disease patients on dialysis.
The company and Takeda Pharmaceutical announce that FDA Oncologic Drugs Advisory Committee voted 15 to 1, with 1 abstention, that peginesatide demonstrated a favorable benefit/risk profile for use in the treatment of dialysis patients with anemia due to chronic kidney disease.
While the FDA is not bound by the recommendations of its advisory committees, their guidance will be considered by the FDA in its review of the New Drug Application that was submitted for peginesatide in May 2011. The scheduled Prescription Drug User Fee Act date for peginesatide is March 27, 2012.
The company and Takeda Pharmaceutical announce that FDA Oncologic Drugs Advisory Committee voted 15 to 1, with 1 abstention, that peginesatide demonstrated a favorable benefit/risk profile for use in the treatment of dialysis patients with anemia due to chronic kidney disease.
While the FDA is not bound by the recommendations of its advisory committees, their guidance will be considered by the FDA in its review of the New Drug Application that was submitted for peginesatide in May 2011. The scheduled Prescription Drug User Fee Act date for peginesatide is March 27, 2012.
